Hikma inks distribution deal with Civica Rx

Press enter to search
Close search
Open Menu

Hikma inks distribution deal with Civica Rx

By Sandra Levy - 08/20/2019
Hikma Pharmaceuticals has inked a five year deal with Civica Rx to manufacture and supply Civica's growing membership of U.S. health systems with medications that often are in short supply.

"We applaud Hikma's clear commitment to reducing drug shortages," said Martin VanTrieste, president and CEO of Civica Rx. "Our partnership will help us make an impact as quickly as possible. We specifically chose Hikma because of their strong manufacturing capabilities and believe their excellent quality and supply record will be key to our success in ensuring vital medications are consistently available for hospitals and patients who need them."

Hikma will produce 14 essential sterile injectable medications for Civica as a private-label distributor, using Hikma's abbreviated new drug applications and Civica's labeling and National Drug Code.

"Hikma is thrilled to be partnering with Civica to reduce drug shortages, and we share their commitment to providing hospitals and doctors with a steady and reliable supply of high-quality injectable medicines needed for successful patient care," said Daniel Motto, Hikma's executive vice president of commercial & business development, U.S. injectables. "This agreement recognizes both our ability to deliver a large and consistent supply of quality medicines, and the significant investments we have made to expand our injectable manufacturing capacity and capabilities."

The list of products included in the agreement will be publicly announced in the near future, and initial shipments are expected to begin before the end of 2019.

“We are privileged to be working with Civica and we appreciate their five-year commitment to guaranteed demand and fair and sustainable pricing, which supports more effective production planning and long-term investments in manufacturing," said Riad Mishlawi, Hikma injectables president. "We believe Hikma's size and scale, broad portfolio of medicines and robust pipeline across growing therapeutic areas will enable us to build on this partnership in the future.